Update REAME.md

REAME.md

@@ -0,0 +1,74 @@
+---
+language: en
+license: cc-by-nc-4.0
+tags:
+- medical
+- oncology
+- genomics
+- synthetic-data
+- ehr
+- electronic-health-records
+pretty_name: Clinical EHR & Somatic Genomics Dataset (Breast Cancer Cohort)
+size_categories:
+- 10K<n<100K
+task_categories:
+- text-generation
+- token-classification
+---
+
+# 🧬 EHR & Somatic Genomics Synthetic Oncology Dataset (AnodeAI)
+
+This dataset contains highly structured, multi-modal synthetic clinical oncology records coupled with Next-Generation Sequencing (NGS) somatic variant profiles and longitudinal electronic health records (EHR). 
+
+Unlike standard stochastic mock data, this dataset is engineered via a **deterministic clinical logic engine** that guarantees 100% biological and pharmacological integrity across all fields.
+
+---
+
+## 💡 Key Architectural Highlights
+* **Zero Hallucinations:** Strict internal constraints prevent medical contradictions (e.g., Triple-Negative profiles will never mistakenly receive HER2-targeted therapies).
+* **Multi-Modal Synchronization:** Seamlessly unifies three typically isolated clinical data silos: clinical staging/phenotypes, digital molecular diagnostics (IHC/NGS), and longitudinal real-world evidence (RWE).
+* **Mathematical Outcome Correlation:** Progression-Free Survival (PFS) metrics are statistically correlated with Response Evaluation Criteria in Solid Tumors (RECIST 1.1) values to preserve downstream machine learning utility.
+
+---
+
+## 📊 Schema & Clinical Logic Deep Dive
+
+### 1. Patient Demographics
+Contains basic baseline parameters for tracking patient cohorts.
+* `patient_id`: Unique tracking identifier prefixed for institutional indexing.
+* `age` / `gender` / `ethnicity`: Demographically balanced variables tailored to replicate true epidemiological distributions in oncology.
+
+### 2. Clinical Oncology Profile
+Establishes the specific breast cancer phenotypic anchor, which strictly drives the rest of the record:
+* **Hormone Receptor Positive (HR+/HER2-)**: Characterized by elevated ER/PR percentages and negative HER2 IHC statuses.
+* **HER2 Positive (HER2+)**: Configured with amplified HER2 expressions (3+ by IHC) and varying hormone receptor profiles.
+* **Triple-Negative Breast Cancer (TNBC)**: Enforces absolute zero/negative values for ER, PR, and HER2 receptors.
+
+### 3. Genomic Sequencing Data
+Simulates a targeted Next-Generation Sequencing (NGS) assay reporting somatic variants matching the patient's biological subtype:
+* **HR+/HER2- Pool**: Features highly relevant driver alterations such as *PIK3CA* (e.g., `p.E545K`, `p.H1047R`) and *ESR1* (`p.D538G`).
+* **HER2+ Pool**: Maps copy-number variations like *ERBB2* amplifications alongside *TP53* mutations.
+* **TNBC Pool**: Integrates pathogenic tumor-suppressor variants in *BRCA1*, *BRCA2*, and *TP53*.
+* `variant_allele_frequency_vaf`: Synthesized as a continuous float value ($0.05 \le \text{VAF} \le 0.65$) indicating structural clone density.
+
+### 4. Longitudinal Treatment & RWE
+Tracks the active first-line therapeutic journey, mapping outcomes precisely to standard oncology reporting frameworks:
+* `regimen_administered`: Pairs standard-of-care protocols seamlessly to biomarkers (e.g., CDK4/6 inhibitors for HR+, anti-HER2 monoclonal antibodies for HER2+, checkpoint inhibitors for TNBC).
+* `adverse_events_ctcae_v5`: Captures severe toxicities (Grades 2-4) linked explicitly to the administered drug toxicological profile, including exact clinical intervention steps (`action_taken`).
+* `treatment_response_recist_1_1`: Classifies patient response into standard categories (`CR`, `PR`, `SD`, `PD`).
+* `progression_free_survival_months`: Employs hard-coded survival boundaries to match the clinical response (e.g., restricting progressive disease to rapid relapse ranges while scaling complete responses past 2-5 years).
+
+---
+
+> ## ⚡ COMMERCIAL LICENSING & ENTERPRISE ACCESS
+> 
+> **IMPORTANT NOTICE:** The dataset version hosted on Hugging Face is published under the **Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)** license. It is strictly limited to academic research, open-source benchmarking, and local sandbox prototyping.
+>
+> ### 🚀 Looking for Commercial Scale or Custom Disease Cohorts?
+> If your organization requires high-fidelity synthetic clinical data for commercial production, enterprise AI training pipelines, or software dashboard validation, we offer scalable production engines.
+> 
+> * **Production Volumes:** Instantly generate from 10,000 to 1,000,000+ perfectly clean, fully validated clinical records.
+> * **Expanded Pathologies:** Custom logic modules available for **Non-Small Cell Lung Cancer (NSCLC)**, **Colorectal Cancer (CRC)**, **Melanoma**, and more.
+> * **Standardized Medical Ontologies:** Optional integration of explicit medical coding systems including **ICD-10-CM**, **SNOMED CT**, **RxNorm**, **HGVS**, and **CTCAE numerical codes** for direct production pipeline compatibility.
+> 
+> 📧 **Acquire a Commercial License:** To unlock unrestricted commercial usage rights, purchase full enterprise cohorts, or request bespoke oncology schema adaptations, please contact the engineering team directly at **anodeai.corp@gmail.com** (or via your platform's official contact portal).